By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NovoCure Ltd. 

Bridgeport  Connecticut  06610  U.S.A.
Phone: n/a Fax:


Medical Device

Company News
NovoCure Release: CNS Oncology Publishes Tumor Treating Fields Treatment Planning And Patient Follow-up Guidelines In Glioblastoma 9/19/2016 10:03:13 AM
NovoCure’s Executive Chairman William Doyle To Present On Tumor Treating Fields At New York Academy Of Sciences’ Symposium On Bioelectronic Medicine 9/15/2016 11:20:13 AM
Two Institutions Publish Independent Data On NovoCure’s Tumor Treating Fields 9/14/2016 11:31:02 AM
Long-term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Superior Progression Free And Overall Survival Seen In The Trial’s Interim Analysis 9/12/2016 12:05:39 PM
NovoCure Release: International Journal Of Cancer Publishes Data Showing Tumor Treating Fields In Combination With Paclitaxel Is Therapeutically Effective Against Ovarian Cancer Cells In Vitro And In Vivo 9/1/2016 10:56:28 AM
NovoCure Converts More Than 500 U.S. Patients To Second Generation Optune Within Four Weeks Of FDA Approval On July 13 8/16/2016 10:08:49 AM
NovoCure To Present At Upcoming Investor Conferences 8/9/2016 11:31:58 AM
NovoCure Reports Second Quarter 2016 Financial Results and Provides Company Update 7/28/2016 11:11:57 AM
NovoCure To Host Research And Development Day On Dec. 12, 2016 7/28/2016 11:09:15 AM
NovoCure Release: National Comprehensive Cancer Network Guidelines Recommend Optune As A Standard Treatment Option For Newly Diagnosed Glioblastoma 7/26/2016 10:06:41 AM